Comprehensive Multiple Myeloma Treatment Plan for Nurse Coordinators
Initial Workup and Diagnosis
Obtain whole-body low-dose CT scan as the preferred imaging modality for baseline bone surveillance 1, 2. FDG-PET/CT or MRI serve as acceptable alternatives at baseline and for specific situations like risk-stratifying smoldering myeloma or monitoring nonsecretory disease 2.
Key Diagnostic Elements:
- Assess for plasma cell accumulation in bone marrow
- Evaluate for end organ damage: hypercalcemia, renal failure, anemia, bone lesions
- Perform cytogenetic testing for risk stratification
- Measure monoclonal protein levels and free light chains
Treatment Pathway Algorithm
Step 1: Determine Transplant Eligibility
Do not use chronologic age or renal function alone to determine stem cell transplant (SCT) eligibility 2. Consider overall functional status, comorbidities, and frailty assessment.
For Transplant-Eligible Patients
Induction Therapy (3-4 cycles)
Administer daratumumab plus bortezomib/lenalidomide/dexamethasone (D-VRd) as the preferred induction regimen 1. This combination achieved:
- 67% stringent complete response rate
- 64.8% MRD-negative status for ≥12 months
- 4-year progression-free survival advantage
Critical nursing considerations:
- Monitor for grade 3-4 neutropenia (62.1% incidence) and thrombocytopenia (29.1% incidence) 1
- Administer granulocyte colony-stimulating factor for high-risk patients 2
- Avoid melphalan or prolonged immunomodulatory drug exposure (>4 cycles) before stem cell collection 2
Stem Cell Collection
Collect sufficient stem cells for more than one transplant upfront 2. Proceed to SCT regardless of depth of response after induction 2.
High-Dose Therapy and Transplant
Administer high-dose melphalan followed by autologous SCT 2. Do not routinely recommend tandem autologous SCT 2.
Maintenance Therapy
Initiate lenalidomide maintenance (Category 1 preferred) starting at day 90-110 at 10-15 mg daily until progression 1, 2.
For high-risk cytogenetics: Use two-drug maintenance with proteasome inhibitor plus lenalidomide 1, 2. Alternative options include:
- Carfilzomib/lenalidomide
- Daratumumab/lenalidomide
- Bortezomib ± lenalidomide 1
Important caveat: Discuss increased risk of secondary cancers with lenalidomide maintenance post-transplant, particularly for high-risk patients 1.
For Transplant-Ineligible Patients
Initial Therapy
Prescribe triplet therapy with bortezomib/lenalidomide/dexamethasone as the standard approach 2. Daratumumab plus bortezomib/melphalan/prednisone represents an alternative triplet option 2.
Individualize initial dosing based on:
- Age and frailty status
- Renal function (adjust lenalidomide/pomalidomide starting doses)
- Comorbidities and functional status
- Peripheral neuropathy risk 2
Continuous vs. Fixed Duration
Administer continuous therapy over fixed-duration therapy when using immunomodulatory drug or proteasome inhibitor-based regimens 2.
Supportive Care Management
Cytopenias
For anemia (grade 3-4 in 3-19% of cases):
- Consider erythropoiesis-stimulating agents if myeloma-related anemia persists despite chemotherapy
- Optimize iron supplementation 2
For thrombocytopenia:
- Reduce doses with proteasome inhibitors and immunomodulatory drugs
- Interrupt treatment for grade 4 thrombocytopenia 2
For neutropenia:
- Administer G-CSF for high-risk patients, especially with daratumumab or immunomodulatory drugs in relapsed settings 2
Renal Impairment
Select agents based on renal function:
- Bortezomib and thalidomide: No dose adjustment required
- Lenalidomide and pomalidomide: Adjust starting dose
- Bortezomib provides rapid free light chain clearance, accelerating kidney response 2
For acute renal insufficiency: Consider cyclophosphamide/bortezomib/dexamethasone initially, then switch to proteasome inhibitor/lenalidomide/dexamethasone after renal function improves 1.
Bone Disease
Administer bisphosphonates as backbone supportive care for osteoporosis and lytic lesions 2.
Response Monitoring
Assess depth of response with each treatment cycle 2. Once best response is achieved or during maintenance, monitor at minimum every 3 months 2.
Do not modify treatment based on MRD status outside clinical trials 2. While MRD-negative status correlates with improved outcomes, it should not guide treatment goals in routine practice 2.
Relapsed Disease Considerations
Salvage or delayed SCT may be used as consolidation at first relapse for patients who did not proceed to transplant initially 2.
Individualize treatment of biochemically relapsed myeloma based on:
- Tolerance of prior treatment
- Rate of rise of myeloma markers
- Cytogenetic abnormalities 2
Nurse Coordinator Responsibilities
Coordinate care transitions between treatment phases, particularly for novel immunotherapies like CAR T-cell therapy and bispecific antibodies 3. This includes:
- Patient education on treatment expectations and side effects
- Seamless handoffs between inpatient and outpatient settings
- Monitoring for class-specific toxicities with targeted agents 4
Assess and manage long-term effects as patients now live longer with relapsing-remitting disease 5. Focus on quality of life maintenance throughout protracted treatment courses 5, 6.
Monitor for novel agent-specific toxicities that differ from traditional chemotherapy, requiring updated knowledge and skills 6, 4.